Commercializationv1 · 10.19
Enspryng expands into thyroid eye disease: a different target and a different way to treat ↗
How much can easier administration contribute to treatment initiation and drug sales in thyroid eye disease?
The US approved Enspryng for adult thyroid eye disease. SatraGO-2 met its primary endpoint, whereas SatraGO-1 did not. Maintenance dosing is a subcutaneous injection every four weeks, with home administration possible after training.
- New US indication approvedRecorded
- Track patient uptakeUnverified
- Compare indication-specific salesUnverified
New question opened
Record the new indication, the two trial outcomes and the administration route, and begin tracking uptake and indication-specific sales.
NEXT CHECK
Follow disclosed new treatment starts, switches from other therapies and indication-specific sales in thyroid eye disease, separately from total Enspryng revenue.